Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Br J Cancer. 2023 Feb;128(4):704. doi: 10.1038/s41416-023-02159-4.
No abstract available

Publication types

  • Published Erratum